EP
ORKA

Essential Partners’s Oruka Therapeutics ORKA Stock Holding History

Essential Partners’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05K Sell
11
-16
-59% -$1.07K ﹤0.01% 2231
2026
Q1 		$1.32K Hold
27
– – ﹤0.01% 2149
2025
Q4 		$818 Hold
27
– – ﹤0.01% 2093
2025
Q3 		$519 Buy
+27
New +$400 ﹤0.01% 2197

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Essential Partners's ORKA Position: Q2 2026 in Review

Essential Partners reduced its Oruka Therapeutics (ORKA) stake by 59% in Q2 2026, selling an estimated $1.07K and leaving 11 shares worth $1.05K. The position accounts for ﹤0.01% of the portfolio, ranked #2231.

Essential Partners first reported a position in ORKA in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.32K in Q1 2026. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Essential Partners held 11 shares of Oruka Therapeutics worth $1.05K as of Q2 2026.
  • Essential Partners sold 16 Oruka Therapeutics shares in Q2 2026, an estimated $1.07K.
  • Oruka Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2231 holding.
  • Essential Partners first reported a position in Oruka Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Essential Partners's Oruka Therapeutics position peaked at $1.32K in Q1 2026.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.